Only 1 in 2 new drugs listed last year

24 drugs applied to HIRA’s Pharmaceutical Benefit Committee

11 reimbursement, 3 non-reimbursement, & 10 managed-entry

Of the 24 new drugs that were applied for benefits last year, 12 were successful in listed drugs, with the listing rate remaining at 50%.

 

Dailypharm analyzed new drugs that were deliberated and voted by the HIRA's Pharmaceutical Benefit Committee last year.

 

Of the 24 drugs, only 11 received reimbursed.

 

The remaining 10 drugs were non-reimbursed, and 3 drugs were managed-entry.

 

In particular, Radicut(Edaravone), a drug for treating Amyotrophic Lateral Sclerosis in Mitsubishi Tanabe Pharma Korea Co., Ltd, received a reimbursement judgment at the Pharmaceutical Benefit Committee, and chose the reimbursement withdrawal during drug price negotiations with the NHIS.

 

At the time, Radicut had been discussing the reimbursement in Canada at the same time as Korea, and withdrew Korea's reimbursement entry to enter Canada's reimbursement.

 

Korea's passing of drugs started with Novartis' asthma treatment ‘Xolair (Omalizumab)’ last year.

 

10 of the 13 drugs besides reimbursed determination were clinical benefits but received managed-entry due to higher cost than alternative drugs.

 

Among these, 'Agotin' (agomelatin) of Whanin Pharmaceuticals, 'Faslodex' (Fulvestrant) of AstraZeneca, and ‘Biktarvy’ (Bictegravir) of Gilead Science Korea, accepted the proposed expenses presented by the HIRA and put them on the reimbursed list.

 

Since five domestic companies applied for benefits at the same time, the treatment for chronic constipation of Prucalopride succinate, which was put on the level in last October, was also managed-entry, but only Yooyoung Pharmaceutical is expected to negotiate with the HIRA.

 

Liporaxel (oral Paclitaxel) of Dae Hwa pharmaceutical get approved as a managed-entry in last November after two attempts, and is struggling whether to make a decision.

 

There were four drugs which is non-reimbursed at the drug committee, and Non-reimbursement is determined when both relative clinical usefulness and cost effectiveness are unclear.

 

To challenge again, new cost-effectiveness data must be submitted, evaluated, and the agenda should be addressed to Pharmaceutical Benefit Committee.

 

Non-reimbursed drugs include 'Duodopa intestinal gel' (levodopa)' by Korea's AbbVie, 'Neuronata-R(autologous bone marrow-derived mesenchymal stem cells)' by Corestem, and 'Zerbaxa' (Ceftolozane/Tazobactam) by MSD Korea, Imfinzi (Durvalumab) by AstraZeneca.